Cradle

NEWS: UCB advances its digital antibody engineering program with new Cradle collaboration. The collaboration adds Cradle’s end-to-end platform to UCB’s computational capabilities, supporting faster discovery of complex therapies for severe diseases.

Full article:
cradle.bio/blog/ucb

Fab antibodies can be significant drug candidates, and their small, multi-chain structure presents a challenge in protein engineering. We tried out two approaches, with some surprising results.

cradle.bio/blog/fab-test

Last year, Cradle was one of 29 organizations to participate in the AIntibody Challenge: Design antibodies against the same antigen and lock their sequences in before anything was expressed.

Every entry expressed as a full-length IgG by a single vendor. Affinity and developability were measured blindly–the labs doing the testing did not know whose antibody was in which tube. The results are now published in Nature Biotechnology.

Twenty-nine organizations submitted antibody designs blind. Cradle’s design challenge entry came back at 8.69 pM, and cleared the developability criteria.

cradle.bio/blog/aintibody

We have joined A-Alpha Bio, Dyno Therapeutics, Boltz, and GSK in a mission to solve the bottleneck holding AI protein engineering back: data!

More on the Atlas Consortium:

aalphabio.com/media/a-alpha-…

Exciting: We are among Headline's AI Europe 100! 🎉